Published in Cancer Res on July 01, 2003
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.79
Scheduling of anticancer drugs: timing may be everything. Cell Cycle (2012) 0.78
The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology. ISRN Oncol (2012) 0.77
Hyperspectral and multispectral bioluminescence optical tomography for small animal imaging. Phys Med Biol (2005) 3.11
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res (2004) 2.46
Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med (2004) 2.26
A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell (2006) 2.20
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med (2004) 2.05
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging (2004) 1.76
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol (2004) 1.72
Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med (2002) 1.72
Tetrazine-trans-cyclooctene ligation for the rapid construction of 18F labeled probes. Chem Commun (Camb) (2010) 1.69
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med (2002) 1.60
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging (2004) 1.60
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology (2002) 1.53
Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res (2006) 1.52
Activation and inhibition of the micturition reflex by penile afferents in the cat. Am J Physiol Regul Integr Comp Physiol (2008) 1.37
Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ₃ targeted PET tracer based on a cyclic RGD peptide. Bioorg Med Chem Lett (2011) 1.36
Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU. Nat Protoc (2007) 1.35
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc (2007) 1.27
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition. J Biol Chem (2010) 1.25
Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist (2009) 1.25
Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev (2010) 1.24
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (2012) 1.19
Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets. J Nucl Med (2013) 1.19
Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One (2012) 1.18
Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol (2002) 1.16
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A (2011) 1.16
Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev (2010) 1.14
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A (2008) 1.14
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci (2009) 1.13
In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression. Eur J Nucl Med Mol Imaging (2007) 1.13
Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn (2003) 1.12
Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res (2013) 1.10
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol (2005) 1.10
Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging (2005) 1.10
Automated synthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module. Nucl Med Biol (2010) 1.09
Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res (2006) 1.09
Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression. Bioconjug Chem (2010) 1.08
Tumor quantification in clinical positron emission tomography. Theranostics (2013) 1.06
Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging (2004) 1.05
Conditional and continuous electrical stimulation increase cystometric capacity in persons with spinal cord injury. Neurourol Urodyn (2010) 1.05
Mechanisms of reflex bladder activation by pudendal afferents. Am J Physiol Regul Integr Comp Physiol (2010) 1.03
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med (2013) 1.02
Rapid aqueous [18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun (Camb) (2011) 1.02
[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med (2008) 1.01
Efficient 18F labeling of cysteine-containing peptides and proteins using tetrazine-trans-cyclooctene ligation. Mol Imaging (2013) 1.01
Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT. PLoS One (2009) 1.01
Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest (2010) 1.00
An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol (2009) 1.00
[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr (2007) 0.99
[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol (2008) 0.99
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res (2005) 0.99
Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling. Dalton Trans (2009) 0.98
Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials (2013) 0.98
Intraurethral stimulation evokes bladder responses via 2 distinct reflex pathways. J Urol (2009) 0.97
Excitation properties of the right cervical vagus nerve in adult dogs. Exp Neurol (2010) 0.96
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol (2007) 0.96
Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: facile generation of positron emission tomography/fluorescence dual modality agents for tumor imaging. Theranostics (2013) 0.95
Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model. PLoS One (2011) 0.95
Musculoskeletal system. Semin Nucl Med (2004) 0.95
Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT. Eur J Nucl Med Mol Imaging (2007) 0.93
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol (2011) 0.93
Nonlinear Random Effects Mixture Models: Maximum Likelihood Estimation via the EM Algorithm. Comput Stat Data Anal (2007) 0.93
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med (2013) 0.92
Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother (2006) 0.92
Receptor mediated uptake of a radiolabeled contrast agent sensitive to beta-galactosidase activity. Nucl Med Biol (2003) 0.91
A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano (2014) 0.90
Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm (2012) 0.90
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol (2010) 0.89
Biglycan overexpression on tooth enamel formation in transgenic mice. Anat Rec (Hoboken) (2008) 0.89
Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med (2007) 0.89
RGD-based PET tracers for imaging receptor integrin αv β3 expression. J Labelled Comp Radiopharm (2013) 0.88
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin Nucl Med (2008) 0.88
2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol (2006) 0.88
The improved syntheses of 5-substituted 2'-[18F]fluoro-2'-deoxy-arabinofuranosyluracil derivatives ([18F]FAU, [18F]FEAU, [18F]FFAU, [18F]FCAU, [18F]FBAU and [18F]FIAU) using a multistep one-pot strategy. Nucl Med Biol (2011) 0.87
Evaluation of 2'-deoxy-2'-flouro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo. Mol Imaging (2003) 0.87
FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep (2003) 0.87
18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun (2006) 0.87
Trackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging. Theranostics (2011) 0.87
"Kit like" (18)F labeling method for synthesis of RGD peptide-based PET probes. Am J Nucl Med Mol Imaging (2013) 0.86
Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals. Chemistry (2011) 0.86
A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. Amino Acids (2011) 0.86
Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment. Mol Imaging Biol (2012) 0.86
Urethral flow-responsive afferents in the cat sacral dorsal root ganglia. Neurosci Lett (2012) 0.86
Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol Imaging Biol (2006) 0.85
Synthesis and evaluation of 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression. J Nucl Med (2004) 0.85
Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol Imaging Biol (2012) 0.84
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. J Nucl Med (2012) 0.84
Radiosynthesis of 2'-deoxy-2'-[18F]-fluoro-5-methyl-1-beta-L-arabinofuranosyluracil ([18F]-L-FMAU) for PET. Appl Radiat Isot (2007) 0.84
An improved synthesis of 1'-[18F]fluoroethyl-β-D-lactose ([18F]-FEL) for positron emission tomography imaging of pancreatic cancer. J Labelled Comp Radiopharm (2013) 0.84
Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide. Bioconjug Chem (2011) 0.84